CJC-1295 + Ipamorelin

Overview

CJC-1295 (No DAC) and Ipamorelin are each studied for their effects on growth hormone secretion through independent receptor systems. CJC-1295 (No DAC) — also referred to as Modified GRF (1-29) — is a synthetic GHRH analog that binds to GHRH receptors on pituitary somatotrophs, with downstream Gs-coupled cAMP signaling examined in the context of pulsatile GH release research. Ipamorelin is a selective synthetic ghrelin receptor agonist (GHSR-1a) studied for its effects on GH secretion through a separate intracellular pathway. Its selectivity for GH over cortisol and prolactin has been noted in preclinical and early pharmacological research as a distinguishing characteristic within the GH secretagogue class.

Together, these compounds represent complementary activators of the GH axis studied for dual-pathway GH secretagogue research. Detailed research findings for each individual compound are available on their respective product pages.

Chemical Profile

CJC-1295 (No DAC) — Modified GRF (1-29)

Ipamorelin (NNC 26-0161)

Research Findings

Dual-Pathway GH Axis Research

CJC-1295 (No DAC) and Ipamorelin activate GH secretion through distinct receptor systems — the GHRH receptor and the ghrelin receptor (GHSR-1a), respectively — allowing researchers to examine dual-pathway stimulation of pituitary somatotroph activity. Preclinical models and early pharmacokinetic research have examined each compound individually for dose-dependent GH secretion profiles, IGF-1 axis dynamics, and pulsatile release characteristics. Ipamorelin’s selectivity for GH over other pituitary hormones has been examined in GH secretagogue research. Studies examining dual-pathway GH secretagogue combinations have investigated additive effects on GH secretion and downstream IGF-1 dynamics in experimental settings. Detailed research findings for each compound are available on their individual product pages.

Areas of Research

• Dual-pathway GH axis pharmacology research
• GHRH receptor and ghrelin receptor signaling studies
• Pulsatile GH release dynamics modeling
• IGF-1 axis activity and downstream signaling research
• GH secretagogue selectivity and combination studies

Research Use Only: This product is sold exclusively for laboratory and scientific research. It is not approved for human or veterinary use or consumption.

Disclaimer: All products distributed by Resolve Peptides are supplied exclusively for controlled laboratory and scientific research. They are not drugs, supplements, or therapies, and have not been approved by the FDA or any regulatory authority for human or veterinary use. These products are not intended for human or veterinary administration. Regulatory status of research peptides is subject to change; it is the responsibility of the researcher to verify current applicable regulations in their jurisdiction prior to purchase. Any references to biological effects are based solely on experimental and preclinical data.